PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen

2011-05-24
(Press-News.org) In a study to be published online this week in the Proceedings of the National Academy of Sciences, researchers report the discovery of a novel hepatitis C-like virus in dogs. The identification and characterization of this virus gives scientists new insights into how hepatitis C in humans may have evolved and provides scientists renewed hope to develop a model system to study how it causes disease.

The research was conducted at the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health, the University of Edinburgh, the Center for the Study of Hepatitis C and Pfizer Veterinary Medicine.

Human hepatitis C virus (HCV) affects approximately 200 million people worldwide. According to the Centers for Disease Control and Prevention (CDC), 3.2 million people in the United States are chronically infected. The majority of these patients do not know they are carrying the virus, thus serving as a source of infection for others. HCV, which can cause liver disease and liver cancer, is most often transmitted following large or repeated exposure to infected blood. Persons who use injection drugs; are HIV-positive; or are children of infected mothers have the highest risk of infection.

The discovery of canine hepatitis C virus (CHV) marks the first known instance of hepatitis-like infection in non-human primates and suggests that the virus may have been introduced into human populations through contact with dogs or some other related species more than 500 years ago, long after the domestication of dogs.

CHV belongs to a group of viruses known as hepaciviruses, which also includes GBV-B, a virus that causes hepatitis in tamarins, small monkeys from Central and South America. Among these viruses, HCV is most closely related to its canine counterpart, a finding that surprised first author Dr. Amit Kapoor, an investigator in the Center for Infection and Immunity and Assistant Professor of Pathology..

"Considering the origin of HIV," Dr. Kapoor explains, "we expected to find the closest homologs, or genetic relatives, of HCV in non-human primates. However, while we were analyzing samples from dogs involved in outbreaks of respiratory disease, we came upon a virus that was more similar to HCV than other viruses of the same family. So far, we have only detected CHV in sick animals, a few of which had died of unknown causes. Because of its close genetic similarity to HCV, we suggested the name of canine hepacivirus."

According to Dr. Charles Rice, Scientific and Executive Director of the Center for the Study of Hepatitis C at The Rockefeller University and one of the collaborators involved in the study, "the origins of HCV remain a mystery. These findings underscore the need to look beyond primates for clues to the origins of HCV."

Viral zoonoses, infections that are transmitted from animals to humans, account for about 70% of human emerging infectious diseases. Although transmission between species is uncommon, sustained contact over time can increase the likelihood that a virus adapted to infect humans will evolve. Since their domestication about 10,000 years ago, dogs have been close human companions. Whether humans and dogs were independently infected with an ancestral virus by another species or whether dogs infected humans (or vice versa) cannot be determined from this study. There is NO current risk that dogs can infect humans with either HCV or CHV.

Using a sequencing platform provided by Roche 454 Life Sciences and state-of-the-art-molecular techniques, Dr. Kapoor, together with scientists at the University of Edinburg, The Rockefeller University and Pfizer, determined that like HCV, CHV's genome contained RNA secondary structures called GORS that allow viruses to chronically infect their natural hosts. Moreover, the sequence of genes that encode proteins involved in virus infection and replication were very similar between HCV and CHV.

Until recently, studies into how hepatitis C causes disease in humans have been limited by the lack of animal and cell culture models. According to CII Director Dr. Ian Lipkin, "The identification and characterization of CHV signals the advent of a new tractable animal model for hepatitis C. This discovery provides new tools for understanding how this virus causes disease, and will facilitate drug and vaccine research and development."

### END


ELSE PRESS RELEASES FROM THIS DATE:

The Four Loko effect

2011-05-24
The popular, formerly caffeinated, fruity alcoholic beverage, Four Loko, has been blamed for the spike in alcohol-related hospitalizations, especially throughout college campuses. Initially, caffeine was deemed the culprit and the Food and Drug Administration ordered all traces of caffeine to be removed from Four Loko and all other similar beverages. However, according to an upcoming evaluation in Perspectives on Psychological Science, a journal of the Association for Psychological Science, caffeine might not be the primary cause of the spike in hospitalizations. "Four ...

Heart scientists discover protein that may be 1 cause of heart failure

2011-05-24
Researchers at the Peter Munk Cardiac Centre discovered a protein switch which can trigger a cascade of events leading to heart failure, pointing to a new direction for drug development. “Our research suggests that PINK1 is an important switch that sets off a cascade of events affecting heart cell metabolism,” says Dr. Phyllis Billia, principal author, clinician‑scientist and heart failure specialist at the Peter Munk Cardiac Centre. “This could be one of the inciting events in the development of heart failure.” The findings, published today in Proceedings ...

New resource developed to encourage undergraduate research experiences

2011-05-24
NEW YORK – College educators around the nation who are discovering the unique value of research experiences for undergraduate students now have a new tool available to them – a "program in a box" detailing exactly how such experiences can be created, used and implemented. This resource, which is free, will be introduced tomorrow in New York City by the National Center for Women and Information Technology, as part of their annual summit conference. It will soon be available online at http://bit.ly/mAcvYe, and was supported in part by the National Science Foundation. "Hands-on ...

Penn research overturns theory on how children learn their first words

2011-05-24
PHILADELPHIA — New research by a team of University of Pennsylvania psychologists is helping to overturn the dominant theory of how children learn their first words, suggesting that it occurs more in moments of insight than gradually through repeated exposure. The research was conducted by postdoctoral fellow Tamara Nicol Medina and professors John Trueswell, and Lila Gleitman, all of the Department of Psychology in Penn's School of Arts and Sciences and the University's Institute for Research in Cognitive Science, and Jesse Snedeker, a professor at Harvard University. Their ...

Information overload in drug side effect labeling

Information overload in drug side effect labeling
2011-05-24
INDIANAPOLIS – The lists of potential side effects that accompany prescription drugs have ballooned in size, averaging 70 reactions per drug, a number that can overwhelm physicians trying to select suitable treatments for their patients, according to a new study of drug labels. Long lists of drug side effects—whether found in magazine advertisements or in package inserts—are a familiar sight to patients and doctors. Now researchers from the Regenstrief Institute and the Indiana University School of Medicine have quantified just how complex drug labels have become. In ...

States should be allowed to implement key health reform law provisions early, experts say

2011-05-24
NEW YORK, May 23, 2011—More than eight of 10 leaders in health and health care policy (82%) believe states should be allowed to implement key provisions of the Affordable Care Act early with full federal support, ahead of the timeline outlined in the law. Such key provisions include expanding Medicaid eligibility to cover more low-income families and creating insurance exchanges with premium subsidies. Findings are from the latest Commonwealth Fund/Modern Healthcare Health Care Opinion Leaders Survey, which asked respondents about the relative authority states and the federal ...

Used football faceshields are susceptible to breaking on impact

2011-05-24
COLUMBUS, Ohio – Game-worn football faceshields are more susceptible to breaking when subjected to high-velocity impact than are new faceshields, according to recent research. In the study, researchers used an air cannon to hurl baseballs at new and used polycarbonate faceshields. All of the new shields withstood the strongest impact tested, which was designed to match the force of a kick to the face. More than a third of the game-worn faceshields fractured in response to the testing, which included lower forces of impact as well. In a related survey of college football ...

New nanoscale imaging may lead to new treatments for multiple sclerosis

New nanoscale imaging may lead to new treatments for multiple sclerosis
2011-05-24
(Santa Barbara, Calif.) –– Laboratory studies by chemical engineers at UC Santa Barbara may lead to new experimental methods for early detection and diagnosis –– and to possible treatments –– for pathological tissues that are precursors to multiple sclerosis and similar diseases. Achieving a new method of nanoscopic imaging, the scientific team studied the myelin sheath, the membrane surrounding nerves that is compromised in patients with multiple sclerosis (MS). The study is published in this week's online edition of the Proceedings of the National Academy of Sciences ...

Antibody-guided drug works against acute lymphoblastic leukemia

Antibody-guided drug works against acute lymphoblastic leukemia
2011-05-24
HOUSTON — An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7. Patients enrolled in the trial led by investigators at The University of Texas MD Anderson Cancer Center had ALL that resisted other therapies or recurred after treatment. "A response rate of more than 50 percent in this patient population ...

Study links acetaminophen to lower prostate cancer risk

2011-05-24
ATLANTA – May 23, 2011 – A new study from American Cancer Society researchers finds use of 30 tablets a month or more of acetaminophen for five or more years was associated with an estimated 38% lower risk of prostate cancer. The study appears in Cancer Epidemiology, Biomarkers and Prevention and is one of only two studies of prostate cancer to date that have examined the association with acetaminophen use that was both long-term and regular. Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), particularly long-term use, has been associated with modestly ...

LAST 30 PRESS RELEASES:

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

Continuous and fixed-duration treatments result in similar outcomes for CLL

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy

IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

Emergency departments fall short on delivering timely treatment for sickle cell pain

Study shows no clear evidence of harm from hydroxyurea use during pregnancy

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

Early results suggest exa-cel gene therapy works well in children

NTIDE: Disability employment holds steady after data hiatus

Social lives of viruses affect antiviral resistance

Dose of psilocybin, dash of rabies point to treatment for depression

Helping health care providers navigate social, political, and legal barriers to patient care

Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments

Using smartphones to improve disaster search and rescue

Robust new photocatalyst paves the way for cleaner hydrogen peroxide production and greener chemical manufacturing

Ultrafast material captures toxic PFAS at record speed and capacity

Plant phenolic acids supercharge old antibiotics against multidrug resistant E. coli

UNC-Chapel Hill study shows AI can dramatically speed up digitizing natural history collections

OYE Therapeutics closes $5M convertible note round, advancing toward clinical development

Membrane ‘neighborhood’ helps transporter protein regulate cell signaling

Naval aviator turned NPS doctoral student earns national recognition for applied quantum research

Astronomers watch stars explode in real time through new images

[Press-News.org] Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen